Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (244)
  3. Review (13)
  4. Guidelines (10)
  5. Research Letter (9)
  6. Book Section (6)
  7. Editorial (4)
  8. Correspondence (3)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (664)
  2. Department of Medicine (664)
  3. Hematologic Malignancies, Division of (664)
  4. Lymphoma (664)
  5. Population Sciences Research Program (664)
  6. Survivorship Research (170)

More Groups

People
  1. Alison Moskowitz (231)
  2. Andrew Zelenetz (166)
  3. Paul Hamlin (137)
  4. Ariela Noy (136)
  5. David Straus (121)
  6. Maria Palomba (109)

More People

Years
  1. 2025 (12)
  2. 2024 (50)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Annals of Oncology (18)
  5. Blood Advances (18)
  6. Leukemia and Lymphoma (18)

More Publications

Publishers
  1. American Society of Hematology (276)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (33)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (22)

More Publishers

Results (664)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant
    Meeting Abstract

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Age, albumin, and LDH predict outcome of patients with limited stage peripheral T cell lymphoma: A prognostic model developed on 244 cases enrolled in the T cell project 1 by the International T Cell Project Network
    Meeting Abstract

    Hapgood, G.; Civallero, M.; Stepanishyna, Y.; Vose, J. M.; Cabrera, M. E.; Advani, R. H.; Pileri, S. A.; Manni, M.; Horwitz, S. M.; Foss, F. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • CNS relapse in T-cell lymphoma index: A risk score to predict central nervous system relapse in patients with T-cell lymphomas
    Meeting Abstract

    Bhansali, R. S.; Ellin, F.; Cao, M.; Relander, T.; Li, W.; Long, Q.; Ganesan, N.; Stuver, R.; Horwitz, S. M.; Wudhikarn, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma
    Correspondence

    Gu, L.; Oh, Y.; Smith, M. P.; Kurtansky, N. R.; Horwitz, S.; Kahn, N.; Moskowitz, A.; Noor, S. J.; Myskowski, P.; Rotemberg, V.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective International T-cell lymphoma project
    Journal Article

    Chiattone, C.; Civallero, M.; Fischer, T.; Miranda, E.; Manni, M.; Zing, N. P. C.; Pileri, S. A.; Montoto, S.; Horwitz, S. M.; Cabrera, M. E.; more...
    Hematological Oncology (2022)

    Fulltext@MSK | Save
  • Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant
    Meeting Abstract

    Stuver, R.; Mazloom, A.; Ganesan, N.; Horwitz, S. M.; Moskowitz, A. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alliance A059102: A randomized phase II US intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Geyer, S. M.; Barta, S. K.; Amengual, J. E.; Dockter, T.; Wright, C.; Dinner, S.; Hsi, E. D.; Bartlett, N. L.; Horwitz, S. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30
    Meeting Abstract

    Gerlach, M.; Schmitt, S.; Cyprys, P.; Kasper, M. A.; Mai, I.; Vermeer, M. H.; Horwitz, S. M.; Fingerle-Rowson, G.; Vogl, A.; Schumacher, D.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save